Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown promising efficacy during an early-stage trial in heavily pre-treated colorectal cancer. Thus far in the ...
Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell ...
Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., on Sep. 21, 2020. This story was originally published on BioPharma Dive. To receive daily news and ...
Merck (MRK) and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results